Orthobiologic company Bioventus signed a nationwide contract with UnitedHealthcare employer and individual commercial plans this week.
Three things to know:
1. Bioventus’ Durolane and Gelsyn-3 treatments for knee osteoarthritis pain will be made available to UnitedHealth commercial plan members starting Oct. 1.
2. Durolane is a single-injection and Gelsyn-3 is a three-injection hyaluronic acid-based joint fluid treatment.
3. Bioventus plans to expand Durolane into Australia and New Zealand and is launching Durolane SJ — another HA-based product — in both countries later this year.
More articles on devices:
'A dream come true': Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker's spine division stands to gain from 5 acquisitions